Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Daiichi Sankyo
2017-07-13 17:45:01
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Daiichi Sankyo Announces New Analyses of Once-Daily LIXIANA® (edoxaban) to be Presented at the ISTH 2017 Congress
Daiichi Sankyo
2017-07-10 17:45:01
Daiichi Sankyo Announces New Analyses of Once-Daily LIXIANA® (edoxaban) to be Presented at the ISTH 2017
New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Daiichi Sankyo
2017-08-14 17:45:01
New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of
Daiichi Sankyo Cancer Enterprise Pipeline Data Showing Swift Progress in Precision Medicine for Breast Cancer to be Presented at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Daiichi Sankyo
2017-08-14 17:45:01
Daiichi Sankyo Cancer Enterprise Pipeline Data Showing Swift Progress in Precision Medicine for Breast Cancer
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation
Daiichi Sankyo
2017-07-31 14:05:47
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA® (edoxaban) in Patients with
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
Daiichi Sankyo
2017-08-14 17:45:01
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug
Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
Daiichi Sankyo
2017-04-03 17:45:01
Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients
Daiichi Sankyo Cancer Enterprise Showcases New Data on Multiple Compounds at American Association for Cancer Research 2017 Annual Meeting
Daiichi Sankyo
2017-08-14 17:45:01
Daiichi Sankyo Cancer Enterprise Showcases New Data on Multiple Compounds at American Association for Cancer
New analysis demonstrates that insulin-requiring diabetes increases the risk of stroke or systemic embolism in patients with atrial fibrillation
Daiichi Sankyo
2017-01-31 11:45:01
New analysis demonstrates that insulin-requiring diabetes increases the risk of stroke or systemic embolism in
Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA®▼ (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
Daiichi Sankyo
2017-01-03 13:53:44
Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA®▼ (edoxaban) Patients Undergoing Diagnostic
More Stories
